scholarly journals Effect of Trichostatin A on CNE2 Nasopharyngeal Carcinoma Cells - Genome-wide DNA Methylation Alteration

2014 ◽  
Vol 15 (11) ◽  
pp. 4663-4670 ◽  
Author(s):  
Xiao-Li Yang ◽  
Cheng-Dong Zhang ◽  
Hua-Yu Wu ◽  
Yong-Hu Wu ◽  
Yue-Ning Zhang ◽  
...  
Tumor Biology ◽  
2015 ◽  
Vol 37 (1) ◽  
pp. 877-885 ◽  
Author(s):  
Hong Fan ◽  
Zhujiang Zhao ◽  
Yuchao Cheng ◽  
He Cui ◽  
Fengchang Qiao ◽  
...  

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Lin Shen ◽  
Chao Li ◽  
Fang Chen ◽  
Liangfang Shen ◽  
Zhanzhan Li ◽  
...  

AbstractRadioresistance emerges as the major obstacle to nasopharyngeal carcinoma (NPC) treatment, further understanding of underlying mechanisms is necessary to overcome the radioresistance and improve the therapeutic effect. In this study, we first identified a candidate radioresistant-related gene LUC7L2 via CRISPR/Cas9 high-throughput screening and quantitative proteomic approach. Overexpression of LUC7L2 in NPC cells promoted cell viability following exposure to ionizing radiation (IR), while knockdown of LUC7L2 significantly slowed down the DNA replication and impaired cell survival, sensitized NPC-radioresistant cells to IR. Using immunoprecipitation assay, we found SQSTM1, an autophagy receptor, was a potential binding partner of LUC7L2. Down-regulation of LUC7L2 in NPC-radioresistant cells led to reduction of SQSTM1 expression and enhancement of autophagy level. Furthermore, LUC7L2 knockdown in combination with autophagy inhibitor, chloroquine (CQ), resulted in more NPC-radioresistant cell death. Besides, LUC7L2 was obviously distributed in NPC tissues, and high LUC7L2 expression correlated with shorter survival in NPC patients. Our data suggest that LUC7L2 plays a huge part in regulating radioresistance of NPC cells, and serves as a promising therapeutic target in re-sensitizing NPC to radiotherapy.


2015 ◽  
Vol 48 (1) ◽  
pp. 207-214 ◽  
Author(s):  
RUI-LI ZHANG ◽  
LI-XIA PENG ◽  
JUN-PING YANG ◽  
LI-SHENG ZHENG ◽  
PING XIE ◽  
...  

Epigenetics ◽  
2020 ◽  
pp. 1-18
Author(s):  
Kubra Z. Cilkiz ◽  
Emilie C. Baker ◽  
Penny K. Riggs ◽  
Brittni P. Littlejohn ◽  
Charles R. Long ◽  
...  

2012 ◽  
Vol 48 (3) ◽  
pp. 241-250 ◽  
Author(s):  
L Y Ching ◽  
Bonnie H Y Yeung ◽  
Chris K C Wong

Human stanniocalcin 1 (STC1) has recently been identified as a putative protein factor involved in cellular apoptosis. The use of histone deacetylase inhibitor (i.e. trichostatin A (TSA)) and doxorubicin (Dox) is one of the common treatment methods to induce apoptosis in human cancer cells. A study on TSA and Dox-mediated apoptosis may shed light on the regulation and function of STC1 in cancer treatment. In this study, TSA and Dox cotreatment in human nasopharyngeal carcinoma cells (CNE2) elicited synergistic effects on STC1 gene expression and cellular apoptosis. An activation of p53 (TP53) transcriptional activity in Dox- or Dox+TSA-treated cells was revealed by the increased expression levels of p53 mRNA/protein as well as p53-driven luciferase activities. To elucidate the possible involvement of p53 in STC1 gene transcription, a vector expressing wild-type or dominant negative (DN) p53 was transiently transfected into the cells. Both STC1 promoter luciferase constructs and chromatin immunoprecipitation assays did not support the direct role of p53 in STC1 gene transactivation. However, the synergistic effects of p53 on the induction of NF-κB phosphorylation and the recruitment of acetylated histone H3 in STC1 promoter were observed in TSA-cotreated cells. The overexpression of exogenous STC1 sensitized apoptosis in Dox-treated cells. Taken together, this study provides data to show the cross talk of NF-κB, p53, and histone protein in the regulation of STC1 expression and function.


Sign in / Sign up

Export Citation Format

Share Document